1 |
PATEL M R, CONTE M S, CUTLIP D E, et al. Evaluation and Treatment of Patients With Lower Extremity Peripheral Artery Disease: Consensus Definitions From Peripheral Academic Research Consortium (PARC)[J]. J Am Coll Cardiol, 2015, 65(9): 931-941.
|
2 |
SHANMUGASUNDARAM M, MURUGAPANDIAN S, TRUONG H T, et al. Drug-coated balloon in peripheral artery disease[J]. Cardiovasc Revasc Med, 2019, 20(4): 338-343.
|
3 |
MÜLLER-HÜLSBECK S, KEIRSE K, ZELLER T, et al. Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease[J]. J Endovasc Ther, 2016, 23(5): 701-707.
|
4 |
包俊敏, 刘冰, 沈晨阳, 等. 股腘动脉闭塞症的诊断和治疗中国专家共识[J]. 中国循环杂志, 2022, 37(7): 669-676.
|
5 |
LAIRD J R. Limitations of Percutaneous Transluminal Angioplasty and Stenting for the Treatment of Disease of the Superficial Femoral and Popliteal Arteries[J]. J Endovasc Ther, 2006, 13(): II-30.
|
6 |
崔风强, 陈江浩, 王辉, 等. Acotec药物涂层球囊治疗下肢动脉硬化闭塞症的临床效果[J]. 实用医学杂志, 2021, 37(24): 3184-3187.
|
7 |
KICHIKAWA K, ICHIHASHI S, YOKOI H, et al. Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results[J]. Cardiovasc Intervent Radiol, 2019, 42(3): 358-364.
|
8 |
ICHIHASHI S, SHIBATA T, FUJIMURA N, et al. Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement[J]. J Endovasc Ther, 2019, 26(5): 613-620.
|
9 |
PHILLIPS J A, FALLS A, KOLLURI R, et al. Full Drug-Eluting Stent Jacket: Two-Year Results of a Single-Center Experience With Zilver PTX Stenting for Long Lesions in the Femoropopliteal Arteries[J]. J Endovasc Ther, 2018, 25(3): 295-301.
|
10 |
DAVAINE J M, QUERAT J, KALADJI A, et al. Treatment of TASC C and D Femoropoliteal Lesions with Paclitaxel eluting Stents: 12 month Results of the STELLA-PTX Registry[J]. Eur J Vasc Endovasc Surg, 2015, 50(5): 631-637.
|
11 |
MÜLLER-HÜLSBECK S. EluviaTM peripheral stent system for the treatment of peripheral lesions above the knee[J]. Expert Opin Drug Deliv, 2016, 13(11): 1639-1644.
|
12 |
MÜLLER-HÜLSBECK S, KEIRSE K, ZELLER T, et al. Long-Term Results from the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Femoropopliteal Treatment: 3-Year Follow-up[J]. Cardiovasc Intervent Radiol, 2017, 40(12): 1832-1838.
|
13 |
GRAY W A, KEIRSE K, SOGA Y, et al. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial[J]. Lancet, 2018, 392(10157): 1541-1551.
|
14 |
MÜLLER-HÜLSBECK S, BENKO A, SOGA Y, et al. Two-Year Efficacy and Safety Results from the IMPERIAL Randomized Study of the Eluvia Polymer-Coated Drug-Eluting Stent and the Zilver PTX Polymer-free Drug-Coated Stent[J]. Cardiovasc Intervent Radiol, 2021, 44(3): 368-375.
|
15 |
YE W, BÖHME T, FU W, et al. First peripheral drug-eluting stent clinical results from China: 1-year outcomes of the Zilver PTX China study[J]. Front Cardiovasc Med, 2022, 9: 877578.
|
16 |
GOUËFFIC Y, SAUGUET A, DESGRANGES P, et al. A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial[J]. JACC Cardiovasc Interv, 2020, 13(4): 447-457.
|
17 |
GOUËFFIC Y, TORSELLO G, ZELLER T, et al. Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized Trial[J]. Circulation, 2022, 146(21): 1564-1576.
|
18 |
魏立春, 侯培勇, 谷涌泉. 股腘动脉钙化病变腔内治疗技术新进展[J]. 实用医学杂志, 2021, 37(1): 115-120.
|
19 |
FOLEY T R, COTTER R P, KOKKINIDIS D G, et al. Mid-term outcomes of orbital atherectomy combined with drug-coated balloon angioplasty for treatment of femoropopliteal disease[J]. Catheter Cardiovasc Interv, 2017, 89(6): 1078-1085.
|
20 |
FANELLI F, CANNAVALE A, GAZZETTI M, et al. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease[J]. Cardiovasc Intervent Radiol, 2014, 37(4): 898-907.
|
21 |
TEPE G, BESCHORNER U, RUETHER C, et al. Drug-Eluting Balloon Therapy for Femoropopliteal Occlusive Disease: Predictors of Outcome With a Special Emphasis on Calcium[J]. J Endovasc Ther, 2015, 22(5): 727-733.
|
22 |
MICARI A, NERLA R, VADALÀ G, et al. 2-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study[J]. JACC Cardiovasc Interv, 2017, 10(7): 728-734.
|
23 |
STAVROULAKIS K, TORSELLO G, BOSIERS M, et al. 2-Year Outcomes of the Eluvia Drug-Eluting Stent for the Treatment of Complex Femoropopliteal Lesions[J]. JACC Cardiovasc Interv, 2021, 14(6): 692-701.
|
24 |
BAUSBACK Y, WITTIG T, SCHMIDT A, et al. Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients WithFemoropopliteal Arterial Disease[J]. J Am Coll Cardiol, 2019, 73(6): 667-679.
|
25 |
IIDA O, TAKAHARA M, SOGA Y, et al. 1-Year Outcomes of Fluoropolymer-Based Drug-Eluting Stent in Femoropopliteal Practice: Predictors of Restenosis and Aneurysmal Degeneration[J]. JACC Cardiovasc Interv, 2022, 15(6): 630-638.
|